Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05580991

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN1012 in Subjects with Unresectable or Metastatic Advanced Solid Tumors

Status
Active Not Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
27 (actual)
Sponsor
Canwell Biotech Limited · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.

Conditions

Interventions

TypeNameDescription
DRUGCAN1012CAN1012 IT injection (once every 4 weeks)

Timeline

Start date
2022-09-09
Primary completion
2025-06-30
Completion
2025-06-30
First posted
2022-10-14
Last updated
2025-02-13

Locations

1 site across 1 country: China

Regulatory

Source: ClinicalTrials.gov record NCT05580991. Inclusion in this directory is not an endorsement.

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors (NCT05580991) · Clinical Trials Directory